Browse the evidence

The primary efficacy endpoint is percentage change in body weight.

The trial will measure how effective efsubaglutide alfa is at reducing body weight.

The guidelines provide context-specific recommendations tailored to individual patient needs.

Healthcare providers should customize obesity management strategies for individual patients.

The guidelines include recommendations for situations with limited resources.

Providers in resource-limited settings can utilize these guidelines to optimize care.

Among a subgroup of members on tirzepatide, semaglutide, or with exposure to both, 86.5% of members had at least a 5% reduction in body weight from baseline at 6 months.

These medications are effective for significant weight loss in adherent patients.

Cardiac rehabilitation (CR) significantly improves functional capacity, cardiovascular risk factors, and quality of life in patients with obesity.

Practitioners should implement CR programs to enhance health outcomes in obese patients with cardiovascular issues.

Integrating nutrition and incretin therapies may improve weight-loss durability and adherence.

Practitioners should consider integrated approaches for better long-term weight management.

Approximately two-thirds of patients showed stable weight or continued weight loss during the 6 months following their last semaglutide or tirzepatide prescription.

Practitioners can expect that a significant portion of patients may maintain or lose weight after discontinuing GLP-1RA.

Tirzepatide treatment was associated with a mean percentage weight change of -13.3% for 5 mg and -21.3% for 15 mg compared to placebo from randomization to 72 weeks among participants using weight-inducing medications in SURMOUNT-1.

Practitioners can consider tirzepatide as an effective option for weight loss in patients requiring weight-inducing medications.

In SURMOUNT-3, the mean percentage weight change for the maximum tolerated dose of tirzepatide was -26.1% from randomization to 72 weeks among participants using weight-inducing medications.

Practitioners can consider higher doses of tirzepatide for significant weight loss in patients on weight-inducing medications.

Tirzepatide treatment was associated with weight loss comparable to primary study results among participants taking weight-inducing medications.

Practitioners can confidently recommend tirzepatide for weight loss in patients on weight-inducing medications.

Eine Therapie mit GLP-1-RA kann erfolgreich sein, wenn sie mit nicht-medikamentösen Maßnahmen kombiniert wird.

Die Kombination von GLP-1-RA mit Lebensstiländerungen ist entscheidend für den Therapieerfolg.

Progress logging was associated with greater weight loss over time.

Encouraging users to log their progress can lead to better weight loss results.

Retatrutide yields a 24.2% reduction in total body weight at 48 weeks with 63% of participants achieving a total body weight loss of ≥20%.

Retatrutide may be an effective option for significant weight loss in patients.

Tirzepatide treatment resulted in a mean weight loss of 9.94 ± 4.8 kg and a percentage weight loss of 9.7 ± 4.8 % after 4 months.

Tirzepatide can be an effective option for weight management in patients with obesity.

Significant reductions were observed in body weight, BMI, waist circumference, absolute fat mass, body fat percentage, and visceral fat index.

Tirzepatide effectively reduces various measures of body fat in patients with obesity.

Protein supplementation has no negative effects on kidney performance in healthy adults who perform resistance training.

Practitioners can consider protein supplementation safe for kidney health in healthy adults engaged in resistance training.

Protein and amino acid supplements are widely used by military personnel to increase muscle mass, enhance recovery, and support physical performance.

Practitioners should recognize the common use of protein supplements among military personnel for performance and recovery.

The total sample had an overall improvement in both BMI and fat mass.

The diet was effective in reducing BMI and fat mass in the studied population.

Lean body mass was preserved during the intervention.

The diet helped maintain lean body mass, which is crucial for overall health during weight loss.

Intensive lifestyle interventions in people with type 2 diabetes result in weight loss and significant improvements in glycemic control and cardiovascular disease risk factors.

Practitioners should consider lifestyle interventions as a primary strategy for managing type 2 diabetes.

There are various treatments available for obesity, including lifestyle interventions and pharmacotherapy.

Healthcare providers should be aware of the range of treatment options available for obesity.

A balanced, Mediterranean-style diet has convincing cardiovascular benefits at hard endpoint levels.

Practitioners should consider recommending a Mediterranean diet for cardiovascular health.

Different dietary methods are considered appropriate for weight loss according to leading recommendations.

Practitioners can utilize various dietary methods for effective weight loss strategies.

Diet and lifestyle interventions are favored for promoting weight loss in individuals with obesity and type 2 diabetes.

Practitioners should prioritize diet and lifestyle changes for weight management in these populations.